
INFLARX N.V.
Acción · NL0012661870 · IFRX · A2H7A5 (XNAS)
0,83 USD
06.06.2025 23:29
Cotizaciones actuales de INFLARX N.V.
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
---|---|---|---|---|---|
![]() NASDAQ |
IFRX
|
USD
|
06.06.2025 23:29
|
0,83 USD
| 0,83 USD
-0,12 %
|
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
0,00 % | 5,21 % | -45,03 % | -31,68 % | -68,07 % | -48,44 % | -88,92 % |
Asignación de activos
Activo | Porcentaje % |
---|---|
Stock non-US | 49,50 % |
Stock US | 49,12 % |
Cash | 1,38 % |
NotClassified | 0,00 % |
Other | 0,00 % |
Bond | 0,00 % |
Mayores posiciones
Símbolo | ISIN | Nombre | Porcentaje % |
---|---|---|---|
CRL | Charles River Laboratories International Inc | 6,62 % | |
TPL | Texas Pacific Land Corporation | 5,65 % | |
FNV | Franco-Nevada Corporation | 4,85 % | |
PSK | PrairieSky Royalty Ltd | 4,63 % | |
DB1 | Deutsche Börse AG | 4,45 % | |
ASX | ASX Limited | 4,41 % | |
ICE | Intercontinental Exchange Inc | 4,25 % | |
WPM | Wheaton Precious Metals Corp | 4,08 % | |
ADM | Archer-Daniels-Midland Company | 3,93 % | |
MMC | Marsh & McLennan Companies Inc | 3,43 % |
Distribución por regiones
Región | Porcentaje % |
---|---|
North America | 81,33 % |
Europe Developed | 7,36 % |
Australasia | 5,98 % |
Asia Developed | 4,25 % |
Japan | 1,08 % |
Africa/Middle East | 0,00 % |
Asia Emerging | 0,00 % |
Europe Emerging | 0,00 % |
Latin America | 0,00 % |
United Kingdom | 0,00 % |
Distribución por sectores
Sector | Porcentaje % |
---|---|
Finanzdienstleistungen | 33,23 % |
Grundstoffe | 22,05 % |
Energie | 18,96 % |
Gesundheitswesen | 8,10 % |
Immobilien | 7,47 % |
Basiskonsumgüter | 5,46 % |
Industrieunternehmen | 2,44 % |
Technologie | 2,30 % |
Verbrauchsgüter | 0,00 % |
Telekommunikation | 0,00 % |
Perfil de la empresa para INFLARX N.V. Acción
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Datos maestros del fondo
Emisor Horizon Kinetics
Tipo de valor ETF
Nombre Horizon Kinetics Inflation Beneficiaries ETF
Moneda del fondo USD
Categoría World Large-Stock Growth
fund.
Cifras clave del fondo
Tamaño del fondo 631.168,26 EUR
Estrategia de inversión
The investment seeks long-term growth of capital in real (inflation-adjusted) terms. The fund is an actively-managed ETF that seeks to achieve its investment objective by investing primarily in the equity securities of domestic and foreign companies that are expected to benefit, either directly or indirectly, from rising prices (inflation). The fund's investments in equity securities are generally expected to include common stock, ownership units of publicly traded MLPs, and units of royalty trusts. The fund is non-diversified.
Datos de la empresa
Nombre INFLARX N.V.
Empresa InflaRx N.V.
Símbolo IFRX
Sitio web
https://www.inflarx.de
Mercado principal
NASDAQ

WKN A2H7A5
ISIN NL0012661870
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Niels C. Riedemann M.D., Ph.D.
Capitalización de mercado 70 Mio
País Alemania
Moneda USD
Empleados 0,1 T
Dirección Winzerlaer Str. 2, 07745 Jena
Fecha de OPV 2017-11-07
Símbolos de cotización
Nombre | Símbolo |
---|---|
Frankfurt | IF0.F |
NASDAQ | IFRX |
Otras acciones
Los inversores que tienen INFLARX N.V. también tienen las siguientes acciones en su cartera:
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.